OrbiMed invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. The company explores the globe for innovations that will help ensure humanity lives healthier, longer, and more productive lives. OrbiMed's structure combines the focus of specialists dedicated to specific market sectors with the synergies of a broad investment team spanning both public equity and private markets around the world.
OrbiMed manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. It invests across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide.
OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. It is typically a lead investor, seeking to help build our portfolio companies. Its geographic focus includes North America, Asia, Europe, and Israel.
OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. It can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.
Assets under management: $17 billion (as of March 2021)